Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medexus Pharmaceuticals Inc (MDP.TO)

Medexus Pharmaceuticals Inc (MDP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 39,622
  • Shares Outstanding, K 24,458
  • Annual Sales, $ 108,096 K
  • Annual Income, $ 1,221 K
  • 60-Month Beta 2.31
  • Price/Sales 0.22
  • Price/Cash Flow 1.23
  • Price/Book 0.98
Trade MDP.TO with:
  • Price/Earnings ttm 4.09
  • Earnings Per Share ttm 0.29
  • Most Recent Earnings $-0.02 on N/A
  • Latest Earnings Date 06/19/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate -0.01
  • Low Estimate -0.05
  • Prior Year 0.41
  • Growth Rate Est. (year over year) -107.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.47 +10.88%
on 04/18/24
2.00 -18.50%
on 04/29/24
+0.12 (+7.95%)
since 04/17/24
3-Month
1.47 +10.88%
on 04/18/24
2.00 -18.50%
on 04/29/24
-0.12 (-6.86%)
since 02/16/24
52-Week
1.12 +45.54%
on 06/09/23
3.53 -53.82%
on 08/24/23
+0.40 (+32.52%)
since 05/17/23

Most Recent Stories

More News
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®....

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Medexus Announces Fiscal Q3 2024 Results

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto,...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Medexus Schedules Third Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday,...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Stocks in play: Medexus Pharmaceuticals

Plans to host a conference call at 8:00 am Eastern Time on Thursday, November 9, to discuss Medexus's ...

MDP.TO : 1.63 (+0.62%)
Medexus Schedules Second Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November...

MEDXF : 1.1990 (-0.91%)
MDP.TO : 1.63 (+0.62%)
Medexus Announces Full Exercise and Closing of Over-Allotment Option in Bought-Deal Public Offering

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 17, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that, in connection with its recently completed bought-deal...

MDP.TO : 1.63 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.

See More

Key Turning Points

3rd Resistance Point 1.82
2nd Resistance Point 1.76
1st Resistance Point 1.69
Last Price 1.63
1st Support Level 1.56
2nd Support Level 1.50
3rd Support Level 1.43

See More

52-Week High 3.53
Fibonacci 61.8% 2.61
Fibonacci 50% 2.33
Fibonacci 38.2% 2.04
Last Price 1.63
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar